Transcript
A (0:01)
I'm john strum, and this is real talk, mississippi.
A (0:18)
It's July 22, and we have a lot to talk about. As we've discussed before on this podcast today, more kids are being diagnosed with pediatric Ms. Than ever before. And that could simply be the result of greater awareness about Ms. And better methods of detecting and diagnosing Ms. Well, applying that heightened awareness and those better diagnostic methods isn't limited to kids and teens. Add in the fact that people are simply living longer and we see that more people over the age of 50 than ever before are being diagnosed with late onset Ms. But where pediatric Ms. Almost always seems to be of the relapsing, remitting variety, late onset Ms. Is often characterized by a more progressive disease course along with greater motor disability. Joining me today to help us better understand late onset Ms. Is Dr. Jacqueline Nicholas, the system Chief of Neuroimmunology and Multiple Sclerosis at the Ohio Health Multiple Sclerosis Center. But before we get to my conversation with Dr. Nicholas, there are a few other things that you should know about.
A (1:34)
It's been well established that early intervention leads to better outcomes, a better quality of life for people living with Ms. Well, what if that early intervention could start a few years before someone developed ms? Any Ms. Symptoms? Would treatment with a high efficacy, disease modifying therapy keep that person from even developing Ms. Symptoms? Now, technically, that may not be a cure, but here in the real world, it would certainly feel like one. And here in the real world, we may be a step closer to being able to do just that. A few years ago, research results conclusively proved that the Epstein Barr Virus, or ebv, is a trigger for Ms. By itself, it's not considered a cause, but it is a necessary condition. And if you think about a gun for a moment, it's easy to see that without a trigger, that gun never goes off. But here's the other thing that scientists understand. About 95% of the population carries the Epstein Barr virus, and clearly 95% of the population does not have Ms. So is there something about the Epstein Barr virus that doctors can use to predict who will get Ms. And who won't? The answer to that question may rest within research results just published by a team in Vienna, Austria. But first, a little background. Past research has shown that we develop antibodies against a specific part of an EBV protein called EBNA1. Now, getting back to this latest study, the researchers wanted to determine whether the levels of the antibodies that are produced against that part of an EBV protein that EBNA1 could be used as a biomarker to predict a person's risk of developing Ms. So they measured the EBNA1 antibodies in blood samples from 700 people with relapsing remitting MS, as well as 5,000 people who didn't have Ms. To serve as a control group. The Researchers found that 98% of the people with Ms. And 78% of the people without Ms. Had detectable antibodies against a specific region of the Ebna1 protein, and among the people with MS, the levels of this antibody were significantly higher at the time they were diagnosed with Ms. The research team drilled down further and found that among a subgroup of individuals now, these were people for whom the time of their EBV infection could be determined and traced well. Among Those people, the EBNO1 antibodies became detectable within three years of their EBV infection and importantly, about five years before their Ms. Diagnosis. The research team also tested four blood samples from this subgroup. These blood samples were drawn at nine month intervals following the time of their EBV infection, and an analysis of these blood samples showed that the people with consistently high levels of the EBNA1 antibodies were the people who were at the greatest risk of developing Ms. Later on. Specifically, high antibody levels in two or more samples over the three years after the EBV infection was observed in 96% of the people who went on to develop Ms. And only 5.6% of the people who did not develop Ms. Statistically, this means that people with high antibody levels in at least two blood samples following their EBV infection were 400 times more likely to develop Ms. Put plainly, someone for whom high levels of the EBNA1 antibodies are detected at least twice after being infected with the Epstein Barr virus will likely develop Ms. In the following years, and someone with consistently high antibody levels in blood tests following EBV infection will develop Ms. More rapidly. This represents an important development that may lead to proactively screening people who may already be at risk for developing ms, for instance, people who have had mono or those who may have other family members who are already living with Ms. Like all research, this antibody test needs to be validated, but it's a step closer to a simple blood test that could predict Ms. Years before it develops, and that opens a door for proactive treatment before someone experiences even a single Ms. Symptom. If you'd like to review the details of this study, you'll find a link in today's show. Notes.
